Changes of gastric ulcer bleeding in the metropolitan area of Japan

被引:1
作者
Yoko Kubosawa [1 ,2 ]
Hideki Mori [1 ,3 ]
Satoshi Kinoshita [1 ]
Yoshihiro Nakazato [1 ]
Ai Fujimoto [1 ]
Masahiro Kikuchi [1 ]
Toshihiro Nishizawa [1 ,4 ]
Masayuki Suzuki [1 ]
Hidekazu Suzuki [5 ]
机构
[1] Department of Gastroenterology, National Hospital Organization Tokyo Medical Center
[2] Division of Gastroenterology and Hepatology, Department of Internal Medicine, Keio University School of Medicine
[3] Department of Clinical and Experimental Medicine, Translational Research Center for Gastrointestinal Diseases (TARGID), University of Leuven
[4] Department of Gastroenterology, Digestive Disease Center, International University of Health and Welfare, Mita Hospital
[5] Division of Gastroenterology and Hepatology, Department of Internal Medicine, Tokai University School of Medicine
关键词
Helicobacter pylori infection; Gastric ulcer bleeding; Non-steroidal antiinflammatory drugs; Antithrombotic agents;
D O I
暂无
中图分类号
R573.1 [溃疡病];
学科分类号
1002 ; 100201 ;
摘要
BACKGROUND The two main causes of gastric ulcer bleeding are Helicobacter pylori(H. pylori)infection and ulcerogenic medicines, although the number of cases caused by each may vary with age. In Japan, the rate of H. pylori infection has fallen over the last decade and the number of prescriptions for non-steroidal anti-inflammatory drugs(NSAIDs) and antithrombotic drugs is increasing as the population ages.Methods of treatment for gastric ulcer bleeding have advanced with the advent of hemostatic forceps and potassium-competitive acid blocker(P-CAB). Thus,causes and treatments for gastric ulcer bleeding have changed over the last decade.AIM To examine the trends of gastric ulcer bleeding over 10 years in the metropolitan area of Japan.METHODS This is a single-center retrospective study. A total of 564 patients were enrolled from inpatients admitted to our hospital with gastric ulcer bleeding between 2006 and 2016. Age, medication history, H. pylori infection, method of treatment, rateof rebleeding, and the length of hospitalization were analyzed. Factors associated with gastric ulcer bleeding were evaluated using Fisher’s exact test, Pearson’s Chi-squared test or Student’s t-test as appropriate. The Jonckheere-Terpstra test was used to evaluate trends. A per-protocol analysis was used to examine the rate of H. pylori infection.RESULTS There was a significant increase in the mean age over time(P < 0.01). The rate of H. pylori infection tended to decrease over the study period(P = 0.10), whereas the proportion of patients taking antithrombotic agents or NSAIDs tended to increase(P = 0.07). Over time, the use of NSAIDs and antithrombotic drugs increased with age. By contrast, the rate of H. pylori infection during the study period fell with age. H. pylori-induced ulcers accounted for the majority of cases in younger patients(< 70 years old); however, the rate decreased with age(P <0.01). The method of treatment trend has changed significantly over time. The main method of endoscopic hemostasis has changed from clipping and injection to forceps coagulation(P < 0.01), and frequently prescribed medicines have changed from proton pump inhibitor to P-CAB(P < 0.01). The rate of rebleeding during the latter half of the study was significantly lower than that in the first half.CONCLUSION These trends, gastric ulcers caused by ulcerogenic drugs were increasing with age and H. pylori-induced ulcers were more common in younger patients, were observed.
引用
收藏
页码:6342 / 6353
页数:12
相关论文
共 27 条
  • [1] Helicobacter pylori-negative,non-steroidal anti-inflammatory drug:Negative idiopathic ulcers in Asia
    Katsunori Iijima
    Takeshi Kanno
    Tomoyuki Koike
    Tooru Shimosegawa
    [J]. World Journal of Gastroenterology, 2014, (03) : 706 - 713
  • [2] Endoscopic submucosal dissection for gastrointestinal neoplasms[J]. Naomi Kakushima,Mitsuhiro Fujishiro.World Journal of Gastroenterology. 2008(19)
  • [3] The comparison of monopolar hemostatic forceps with soft coagulation versus hemoclip for peptic ulcer bleeding: a randomized trial (with video)[J] . Bilal Toka.Gastrointestinal Endoscopy . 2018
  • [4] Vonoprazan prevents ulcer recurrence during long-term NSAID therapy: randomised, lansoprazole-controlled non-inferiority and single-blind extension study[J] . Yuji Mizokami,Kazunori Oda,Nobuo Funao,Akira Nishimura,Satoshi Soen,Takashi Kawai,Kiyoshi Ashida,Kentaro Sugano.Gut . 2018 (6)
  • [5] Vonoprazan prevents low-dose aspirin-associated ulcer recurrence: randomised phase 3 study[J] . Takashi Kawai,Kazunori Oda,Nobuo Funao,Akira Nishimura,Yasushi Matsumoto,Yuji Mizokami,Kiyoshi Ashida,Kentaro Sugano.Gut . 2018 (6)
  • [6] Proton pump inhibitors: from CYP2C19 pharmacogenetics to precision medicine[J] . El Rouby,Lima,Johnson.Expert Opinion on Drug Metabolism & Toxicology . 2018 (4)
  • [7] Randomised clinical trial: efficacy and safety of vonoprazan vs. lansoprazole in patients with gastric or duodenal ulcers – results from two phase 3, non‐inferiority randomised controlled trials[J] . H. Miwa,N. Uedo,J. Watari,Y. Mori,Y. Sakurai,Y. Takanami,A. Nishimura,T. Tatsumi,N. Sakaki.Alimentary Pharmacology & Therapeutics . 2017 (2)
  • [8] Acid-inhibitory effects of vonoprazan 20mg compared with esomeprazole 20mg or rabeprazole 10mg in healthy adult male subjects - a randomised open-label cross-over study
    Sakurai, Y.
    Mori, Y.
    Okamoto, H.
    Nishimura, A.
    Komura, E.
    Araki, T.
    Shiramoto, M.
    [J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2015, 42 (06) : 719 - 730
  • [9] Time Trends in Helicobacter pylori Infection and Atrophic Gastritis Over 40Years in Japan
    Kamada, Tomoari
    Haruma, Ken
    Ito, Masanori
    Inoue, Kazuhiko
    Manabe, Noriaki
    Matsumoto, Hiroshi
    Kusunoki, Hiroaki
    Hata, Jiro
    Yoshihara, Masaharu
    Sumii, Koji
    Akiyama, Takashi
    Tanaka, Shinji
    Shiotani, Akiko
    Graham, David Y.
    [J]. HELICOBACTER, 2015, 20 (03) : 192 - 198
  • [10] Randomised clinical trial: safety, tolerability, pharmacokinetics and pharmacodynamics of repeated doses of TAK ‐438 (vonoprazan), a novel potassium‐competitive acid blocker, in healthy male subjects[J] . H. Jenkins,Y. Sakurai,A. Nishimura,H. Okamoto,M. Hibberd,R. Jenkins,T. Yoneyama,K. Ashida,Y. Ogama,S. Warrington.Aliment Pharmacol Ther . 2015 (7)